Notice of Intent To Prepare an Environmental Impact Statement for the Proposed Master Plan for the U.S. Food and Drug Administration Muirkirk Road Campus (Prince George's County, Laurel, MD), 83582-83583 [2020-28212]

Download as PDF 83582 Federal Register / Vol. 85, No. 246 / Tuesday, December 22, 2020 / Notices Q2. Should a contractually binding mechanism relate to the provision of capital or liquidity? What classes of assets would be deemed to provide capital vs. liquidity? A2. Contractually binding mechanism is a generic term and includes the down-streaming of capital and/or liquidity as contemplated by the U.S. resolution strategy. Furthermore, it is up to the firm, as informed by any relevant guidance of the Agencies, to identify what assets would satisfy a U.S. affiliate’s need for capital and/or liquidity. Q3. Is there a minimum acceptable duration for a contractually binding mechanism? Would an ‘‘evergreen’’ arrangement, renewable on a periodic basis (and with notice to the Agencies), be acceptable? A3. To the extent a firm utilizes a contractually binding mechanism, such mechanism, including its duration, should be appropriate for the firm’s U.S. resolution strategy, including adequately addressing relevant financial, operational, and legal requirements and challenges. Q4. Not consolidated. Q5. Not consolidated. Q6. The firm may need to amend its contractually binding mechanism from time to time resulting potentially from changes in relevant law, new or different regulatory expectations, etc. Is a firm able to do this as long as there is no undue risk to the enforceability (e.g., no signs of financial stress sufficient to unduly threaten the agreement’s enforceability as a result of fraudulent transfer)? A6. Yes, however the Agencies should be informed of the proposed duration of the agreement, as well as any terms and conditions on renewal and/or amendment. Any amendments should be identified and discussed as part of the firm’s next U.S. resolution plan submission. Q7. Not consolidated. Q8. Should firms include a formal regulatory trigger by which the Agencies can directly trigger a contractually binding mechanism? A8. No [FR Doc. 2020–28155 Filed 12–21–20; 8:45 am] BILLING CODE 6210–01– 6714–01–P FEDERAL RESERVE SYSTEM Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company None of the general FAQs were consolidated. The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act. Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than January 6, 2021. A. Federal Reserve Bank of Minneapolis (Chris P. Wangen, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291: 1. Steven and Laurel Klefstad, Forman, North Dakota; to join the McLaen family shareholder group, a group acting in concert, to retain voting shares of Napoleon Bancorporation, Inc., Napoleon, North Dakota, and thereby indirectly retain voting shares of Stock Growers Bank, Forman, North Dakota. By order of the Board of Governors of the Federal Reserve System. Ann Misback, Secretary of the Board. Board of Governors of the Federal Reserve System, December 17, 2020. Michele Taylor Fennell, Deputy Associate Secretary of the Board. Federal Deposit Insurance Corporation. By order of the Board of Directors. [FR Doc. 2020–28199 Filed 12–21–20; 8:45 am] General jbell on DSKJLSW7X2PROD with NOTICES Dated at Washington, DC, on or about December 7, 2020. James P. Sheesley, Assistant Executive Secretary. VerDate Sep<11>2014 17:30 Dec 21, 2020 Jkt 253001 BILLING CODE 6210–01–P PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 GENERAL SERVICES ADMINISTRATION [Notice-PBS–2020–11; Docket No. 2020– 0002; Sequence No. 41] Notice of Intent To Prepare an Environmental Impact Statement for the Proposed Master Plan for the U.S. Food and Drug Administration Muirkirk Road Campus (Prince George’s County, Laurel, MD) National Capital Region, General Services Administration (GSA). ACTION: Notice of Intent to prepare an Environmental Impact Statement (EIS). AGENCY: Pursuant to the requirements of the National Environmental Policy Act of 1969 (NEPA), the Council on Environmental Quality Regulations, GSA Order, ADM 1095.1F, Environmental Considerations in Decision Making, dated October 19, 1999, and the GSA Public Buildings Service NEPA Desk Guide, GSA plans to prepare an EIS for a proposed Master Plan for the U.S. Food and Drug Administration’s (FDA) Muirkirk Road Campus (MRC), in Laurel, Maryland, located in Prince George’s County. The Master Plan will provide FDA with a structured framework for developing the MRC over the next 20 years. DATES: Applicable: December 22, 2020. FOR FURTHER INFORMATION CONTACT: Marshall Popkin, Office of Planning and Design Quality, Public Buildings Service, GSA, National Capital Region, at 202–919–0026. SUPPLEMENTARY INFORMATION: The GSA intends to prepare an EIS to analyze the potential impacts resulting from the proposed Master Plan to support the FDA MRC, in Laurel, Maryland, located in Prince George’s County. GSA will analyze four alternatives for the proposed MRC Master Plan: (1) No Action Alternative; (2) Development at the Mod 1/Mod 2 site; (3) Hybrid of Alternatives 2 and 4; and (4) Development at the Beltsville Research Facility site. The proposed action is anticipated to impact soils and topography; traffic and transit; water resources; vegetation; wildlife; air quality; greenhouse gases and climate; utilities; and waste management. No permits are required to adopt the Master Plan. Implementation of the Master Plan in the future could require the following permits and authorizations: • Dredge or fill permit under Section 404 of the Clean Water Act • Coastal Zone Management Consistency Determination • State and local permits, including water and wastewater permits, SUMMARY: E:\FR\FM\22DEN1.SGM 22DEN1 Federal Register / Vol. 85, No. 246 / Tuesday, December 22, 2020 / Notices building permits, sediment and erosion control permits, grading permits, and stormwater management permits. Background In 1981, GSA completed an EIS that analyzed the impacts from the construction of new laboratory space at the MRC and the consolidation of four facilities in the Washington, DC, metro area and other sites in St. Louis, MO, and Cincinnati, OH. In 1990, Congress enacted the Food and Drug Revitalization Act that gave GSA the authority to grant contracts to consolidate FDA facilities. To accommodate future growth and further consolidate FDA operations, GSA is preparing an EIS to assess the impacts of development on the MRC and an increase in the employee population of up to approximately 1,800 employees, over a period of 20 years. The purpose of the proposed action is to provide a Master Plan for the MRC to guide future site development. The proposed action is needed to accommodate projected growth at the MRC and provide the necessary office and laboratory space for FDA to conduct complex and comprehensive research and reviews. jbell on DSKJLSW7X2PROD with NOTICES Schedule for Decision-Making A Draft EIS is expected to be released for public review in June 2021. The GSA will hold a public hearing on the impacts of the proposed action in July 2021, and will seek preliminary approval of the MRC Master Plan from the National Capital Planning Commission (NCPC) at NCPC’s September 2021 hearing. A Final EIS will be prepared that will take into consideration all comments received on the Draft EIS, and a Record of Decision is anticipated in spring 2022. Pending completion of NEPA compliance and review by NCPC, GSA anticipates adopting the MRC Master Plan in spring 2022. Scoping Process In accordance with NEPA, a scoping process will be conducted to aid in determining the alternatives to be considered and the scope of issues to be addressed, as well as for identifying the significant issues related to the proposed MRC Master Plan. Scoping will be accomplished through a virtual public scoping meeting; direct mail correspondence to potentially interested persons, agencies, and organizations; and meetings with agencies having an interest in the Master Plan. It is important that Federal, regional, State, and local agencies, and interested VerDate Sep<11>2014 17:30 Dec 21, 2020 Jkt 253001 individuals take this opportunity to identify environmental concerns that should be addressed during the preparation of the EIS. Public Scoping Meeting Due to the ongoing COVID–19 pandemic and state/local requirements for social distancing, a pre-recorded presentation will be available at www.gsa.gov/ncrnepa in lieu of a traditional in-person public scoping meeting. A project phone line [410– 777–9537] has also been set up to listen to the presentation and to leave comments on the proposed Master Plan. The pre-recorded presentation and phone line will be available from January 4, 2021, through February 11, 2021. The GSA is publishing notices in the Washington Post and Prince George’s Post announcing the meeting. Written Comments Agencies and the public are encouraged to provide comments on identification of potential alternatives, information, and analyses relevant to the proposed action. Comments may be provided in writing via mail or email. Verbal comments may also be provided via the project phone line. Written comments regarding the environmental analysis for the proposed MRC Master Plan must be postmarked by February 11, 2021, and sent to the following: Mr. Marshall Popkin, NEPA Compliance Specialist, Office of Planning and Design Quality, Public Buildings Service, U.S. General Services Administration, 1800 F Street NW, Room 4400, Washington, DC 20405. Email: marshall.popkin@gsa.gov using the subject line: FDA MRC Master Plan EIS Comment. Kristi Tunstall Williams, Deputy Director, Office of Planning and Design Quality, Public Buildings Service, National Capital Region, U.S. General Services Administration. [FR Doc. 2020–28212 Filed 12–21–20; 8:45 am] BILLING CODE 6820–Y1–P GENERAL SERVICES ADMINISTRATION [OMB Control No. 3090–0163; Docket No. 2020–0001; Sequence No. 11] Submission for OMB Review; General Services Acquisition Regulation; Information Specific to a Contract or Contracting Action (Not Required by Regulation) Office of Acquisition Policy, General Services Administration (GSA). AGENCY: PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 83583 Notice of request for public comments regarding an extension to an existing OMB information collection. ACTION: Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a previously approved information collection requirement regarding information specific to a contract or contracting action that is not required by regulation. DATES: Submit comments on or before: January 21, 2021. ADDRESSES: Written comments and recommendations for this information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting ‘‘Currently under Review—Open for Public Comments’’ or by using the search function. FOR FURTHER INFORMATION CONTACT: Mr. Clarence Harrison, Procurement Analyst, GSA Acquisition Policy Division, at telephone 202–227–7051 or email GSARPolicy@gsa.gov. SUPPLEMENTARY INFORMATION: SUMMARY: A. Purpose GSA has various mission responsibilities related to the acquisition and provision of supplies, transportation, information technology, telecommunications, real property management, and disposal of real and personal property. These mission responsibilities generate requirements that are realized through the solicitation and award of public contracts. Most GSA procurement-related information collections are required by the Federal Acquisition Regulation (FAR) or General Services Administration Acquisition Regulation (GSAR); each clause requiring such a collection must be individually approved by OMB. However, some solicitations require contractors to submit information specific to that contracting action, such as information needed to evaluate offers (e.g. specific instructions for technical and price proposals, references for past performance) or data used to administer resulting contracts (e.g. project management plans). This information collection is currently associated with GSA’s information collection requirements contained in solicitations issued in accordance with the Uniform Contract Format under FAR Part 14, Sealed Bidding (see GSAR 514.201–1); FAR E:\FR\FM\22DEN1.SGM 22DEN1

Agencies

[Federal Register Volume 85, Number 246 (Tuesday, December 22, 2020)]
[Notices]
[Pages 83582-83583]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-28212]


=======================================================================
-----------------------------------------------------------------------

GENERAL SERVICES ADMINISTRATION

[Notice-PBS-2020-11; Docket No. 2020-0002; Sequence No. 41]


Notice of Intent To Prepare an Environmental Impact Statement for 
the Proposed Master Plan for the U.S. Food and Drug Administration 
Muirkirk Road Campus (Prince George's County, Laurel, MD)

AGENCY: National Capital Region, General Services Administration (GSA).

ACTION: Notice of Intent to prepare an Environmental Impact Statement 
(EIS).

-----------------------------------------------------------------------

SUMMARY: Pursuant to the requirements of the National Environmental 
Policy Act of 1969 (NEPA), the Council on Environmental Quality 
Regulations, GSA Order, ADM 1095.1F, Environmental Considerations in 
Decision Making, dated October 19, 1999, and the GSA Public Buildings 
Service NEPA Desk Guide, GSA plans to prepare an EIS for a proposed 
Master Plan for the U.S. Food and Drug Administration's (FDA) Muirkirk 
Road Campus (MRC), in Laurel, Maryland, located in Prince George's 
County. The Master Plan will provide FDA with a structured framework 
for developing the MRC over the next 20 years.

DATES: Applicable: December 22, 2020.

FOR FURTHER INFORMATION CONTACT:  Marshall Popkin, Office of Planning 
and Design Quality, Public Buildings Service, GSA, National Capital 
Region, at 202-919-0026.

SUPPLEMENTARY INFORMATION: The GSA intends to prepare an EIS to analyze 
the potential impacts resulting from the proposed Master Plan to 
support the FDA MRC, in Laurel, Maryland, located in Prince George's 
County. GSA will analyze four alternatives for the proposed MRC Master 
Plan: (1) No Action Alternative; (2) Development at the Mod 1/Mod 2 
site; (3) Hybrid of Alternatives 2 and 4; and (4) Development at the 
Beltsville Research Facility site. The proposed action is anticipated 
to impact soils and topography; traffic and transit; water resources; 
vegetation; wildlife; air quality; greenhouse gases and climate; 
utilities; and waste management. No permits are required to adopt the 
Master Plan. Implementation of the Master Plan in the future could 
require the following permits and authorizations:

 Dredge or fill permit under Section 404 of the Clean Water Act
 Coastal Zone Management Consistency Determination
 State and local permits, including water and wastewater 
permits,

[[Page 83583]]

building permits, sediment and erosion control permits, grading 
permits, and stormwater management permits.

Background

    In 1981, GSA completed an EIS that analyzed the impacts from the 
construction of new laboratory space at the MRC and the consolidation 
of four facilities in the Washington, DC, metro area and other sites in 
St. Louis, MO, and Cincinnati, OH. In 1990, Congress enacted the Food 
and Drug Revitalization Act that gave GSA the authority to grant 
contracts to consolidate FDA facilities. To accommodate future growth 
and further consolidate FDA operations, GSA is preparing an EIS to 
assess the impacts of development on the MRC and an increase in the 
employee population of up to approximately 1,800 employees, over a 
period of 20 years.
    The purpose of the proposed action is to provide a Master Plan for 
the MRC to guide future site development. The proposed action is needed 
to accommodate projected growth at the MRC and provide the necessary 
office and laboratory space for FDA to conduct complex and 
comprehensive research and reviews.

Schedule for Decision-Making

    A Draft EIS is expected to be released for public review in June 
2021. The GSA will hold a public hearing on the impacts of the proposed 
action in July 2021, and will seek preliminary approval of the MRC 
Master Plan from the National Capital Planning Commission (NCPC) at 
NCPC's September 2021 hearing. A Final EIS will be prepared that will 
take into consideration all comments received on the Draft EIS, and a 
Record of Decision is anticipated in spring 2022. Pending completion of 
NEPA compliance and review by NCPC, GSA anticipates adopting the MRC 
Master Plan in spring 2022.

Scoping Process

    In accordance with NEPA, a scoping process will be conducted to aid 
in determining the alternatives to be considered and the scope of 
issues to be addressed, as well as for identifying the significant 
issues related to the proposed MRC Master Plan. Scoping will be 
accomplished through a virtual public scoping meeting; direct mail 
correspondence to potentially interested persons, agencies, and 
organizations; and meetings with agencies having an interest in the 
Master Plan. It is important that Federal, regional, State, and local 
agencies, and interested individuals take this opportunity to identify 
environmental concerns that should be addressed during the preparation 
of the EIS.

Public Scoping Meeting

    Due to the ongoing COVID-19 pandemic and state/local requirements 
for social distancing, a pre-recorded presentation will be available at 
www.gsa.gov/ncrnepa in lieu of a traditional in-person public scoping 
meeting. A project phone line [410-777-9537] has also been set up to 
listen to the presentation and to leave comments on the proposed Master 
Plan. The pre-recorded presentation and phone line will be available 
from January 4, 2021, through February 11, 2021. The GSA is publishing 
notices in the Washington Post and Prince George's Post announcing the 
meeting.

Written Comments

    Agencies and the public are encouraged to provide comments on 
identification of potential alternatives, information, and analyses 
relevant to the proposed action. Comments may be provided in writing 
via mail or email. Verbal comments may also be provided via the project 
phone line. Written comments regarding the environmental analysis for 
the proposed MRC Master Plan must be postmarked by February 11, 2021, 
and sent to the following: Mr. Marshall Popkin, NEPA Compliance 
Specialist, Office of Planning and Design Quality, Public Buildings 
Service, U.S. General Services Administration, 1800 F Street NW, Room 
4400, Washington, DC 20405.
    Email: [email protected] using the subject line: FDA MRC 
Master Plan EIS Comment.

Kristi Tunstall Williams,
Deputy Director, Office of Planning and Design Quality, Public 
Buildings Service, National Capital Region, U.S. General Services 
Administration.
[FR Doc. 2020-28212 Filed 12-21-20; 8:45 am]
BILLING CODE 6820-Y1-P